Strategic Lateral Moves in Life Sciences

Life sciences careers are supposed to move in one direction: deeper into a therapeutic area, higher up the functional ladder, from Director to VP to SVP to C-suite. The unspoken assumption is that specialization compounds and that the best career strategy is to become the world’s foremost expert in oncology clinical development, or rare disease regulatory affairs, or immunology commercial strategy. This advice is not wrong — but our placement data shows it is incomplete. Among the senior life sciences professionals in our 18-month follow-up dataset, those who made deliberate lateral moves — across therapeutic areas, between pharma and biotech, or from commercial to medical affairs — experienced 18% higher compensation growth over the follow-up period than those who made traditional vertical moves within their existing function and therapeutic area.

This piece examines the specific lateral moves that produce the best outcomes in life sciences, why the compensation premium exists, and how senior pharma and biotech executives can position lateral transitions as strategic advances rather than career detours.

The 18% comp growth advantage

Across our 18-month follow-up surveys of placed life sciences professionals, the compensation growth data for well-structured lateral moves is consistently and materially positive. Professionals who made lateral moves — defined as moves that did not represent a seniority increase at signing but involved a change of therapeutic area, company type, or functional domain — reported average total compensation growth of 32% over the 18-month period. Professionals who made traditional vertical moves (promotion to a higher title within the same function and therapeutic area) reported average growth of 14%. The 18-percentage-point gap is the headline finding, and the mechanism is specific to life sciences.

The lateral-move premium in life sciences comes from two structural sources. First, lateral moves reset the market-rate anchor: a VP of Commercial Operations in oncology who moves laterally to VP of Commercial Operations in rare disease is now priced at the rare disease market rate, which is typically 15–25% above oncology commercial rates because of the smaller candidate pool and the specialized launch expertise required. Second, lateral moves into high-demand areas (cell therapy, GLP-1, ADC development) capture therapeutic-area premiums that internal promotions within a mature therapeutic area cannot access.

Moving between therapeutic areas

The most common and highest-value lateral move in our dataset is the therapeutic-area pivot. A senior clinical development professional moving from cardiovascular to oncology, or from CNS to immunology, brings transferable regulatory and trial-management skills into a therapeutic area where demand for experienced leaders exceeds supply. In our data, therapeutic-area pivots produced average compensation increases of 22% at signing — driven primarily by companies willing to pay premiums for experienced functional leaders even when those leaders lack deep TA-specific backgrounds.

The pivot is most effective when it moves toward therapeutic areas with strong funding and clinical momentum. In the current market, the highest-demand therapeutic areas are: oncology (ADCs and bispecifics), where experienced CMC and clinical development leaders command premiums of 20–30% over equivalent roles in mature therapeutic areas; GLP-1/metabolic disease, where the commercial success of semaglutide and tirzepatide has created a surge in demand for leaders who can build and scale metabolic disease franchises; and cell and gene therapy, where the regulatory and manufacturing complexity creates ongoing demand for experienced leaders regardless of their prior therapeutic-area background.

The therapeutic-area pivot works best when the candidate can articulate the transferable skill. A VP of Clinical Development in cardiovascular disease who has extensive experience designing and executing global Phase III programs brings trial-execution expertise that is directly applicable in oncology — particularly for large, multi-site registrational studies. The therapeutic knowledge can be acquired; the operational expertise in managing 200-site global trials cannot be learned quickly.

Big pharma to biotech transitions

The pharma-to-biotech lateral move is the second most common pattern in our dataset, and it carries specific compensation dynamics that differ from the therapeutic-area pivot. At signing, the pharma-to-biotech move typically involves a cash compensation decrease of 10–20%, offset by equity grants that can represent 30–50% of total compensation at grant. The 18-month follow-up tells the full story: professionals who moved from big pharma to clinical-stage biotechs and whose companies experienced positive clinical catalysts during the follow-up period reported total compensation growth of 45–60%, driven almost entirely by equity appreciation. Those whose companies experienced setbacks reported flat or negative compensation trajectories.

The pharma-to-biotech lateral move is most valuable for professionals in the VP to SVP transition — the career stage where big pharma’s organizational layers create the longest promotion timelines. A VP of Regulatory Affairs at a top-20 pharma company may wait 4–6 years for an SVP promotion, competing against multiple internal candidates in a structured succession process. The same professional can move to a biotech as Head of Regulatory (functionally equivalent to SVP scope) and achieve the title, the board exposure, and the P&L accountability immediately.

Commercial to medical affairs

The most counterintuitive lateral move in our dataset — and one of the highest-performing — is the transition from commercial leadership to medical affairs. This move is counterintuitive because it appears to move away from the revenue-generating side of the business, which traditionally carries higher compensation and clearer career progression. In practice, the move reflects a structural shift in how pharma companies commercialize specialty and rare disease products, where medical affairs (MSL teams, medical education, KOL engagement) has become as important as traditional sales and marketing in driving adoption.

In our data, commercial leaders who transitioned to VP-level medical affairs roles experienced average signing compensation that was 5–8% below their prior commercial comp — a smaller gap than most candidates expected. At the 18-month follow-up, the gap had closed entirely, with medical affairs compensation growing at 12% annually compared to 7% for equivalent commercial roles. The growth reflects the increasing strategic importance of medical affairs in specialty pharma and the premium that companies pay for leaders who bring commercial rigor to medical strategy.

The commercial-to-medical transition is particularly effective for professionals with deep KOL management experience, because the relationship skills transfer directly and the medical affairs side values the commercial perspective on stakeholder engagement that pure medical backgrounds often lack. The professionals in our dataset who made this transition most successfully had typically obtained advanced scientific credentials (PharmD, PhD, or MBA with healthcare focus) earlier in their careers, providing the scientific credibility needed for medical affairs leadership.

How to position the move

The framing challenge of a lateral move in life sciences is specific: the candidate must demonstrate that the move represents strategic breadth-building rather than a failure to advance vertically. Three framing approaches that work in our placement experience:

Lead with the therapeutic-area thesis. “I’ve spent 12 years building deep expertise in clinical trial execution. The next frontier for that expertise is in cell therapy, where the regulatory and operational challenges are uniquely complex and where my trial-management experience directly addresses the biggest bottleneck these companies face.” This framing positions the lateral move as a deliberate application of proven skills to a higher-impact context.

Quantify the scope expansion. “In my current role, I manage the regulatory strategy for one therapeutic area within a 10-TA portfolio. In this role, I own the entire regulatory function for the company — all programs, all geographies, all interactions with FDA, EMA, and PMDA.” The lateral title masks a genuine expansion in operational scope that any experienced hiring manager will recognize.

Connect to the market trajectory. “The ADC space is producing more clinical successes than any other modality in oncology right now. I want to be part of building a franchise in that space rather than optimizing an established product in my current therapeutic area.” This framing shows commercial awareness and strategic thinking that transcends functional expertise.

When to make the lateral move

The lateral move in life sciences produces the best outcomes when made from a position of strength — when the executive has genuine choices and is choosing the lateral path deliberately rather than accepting it as the best available option. Four signals that the timing is right: your current therapeutic area is consolidating (fewer companies, smaller pipelines, fewer clinical programs reaching late-stage development); your current company’s promotion timeline has extended beyond what the market would offer externally; a new therapeutic area or modality is experiencing rapid growth that creates demand for experienced functional leaders regardless of TA background; or your current role has plateaued in scope and you’re no longer developing new capabilities.

The 18% compensation growth advantage for lateral movers in our data reflects a market that values versatile life sciences leaders more than it values deep but narrow specialists. The pharma industry is structurally shifting toward smaller, more agile organizations where leaders must operate across therapeutic areas, functions, and development stages. The executives who are building breadth now — through deliberate lateral moves — are positioning themselves for the C-suite roles that will define the next generation of biopharma leadership. For current compensation benchmarks across life sciences functions, see our 2026 Compensation Report.